- Lab Alumni
Dr. Verma received her Master’s degree in Biotechnology from the University of Pune, India, respectively. She was awarded a gold medal for securing the first rank in her Master’s exam. She went on to obtain her PhD in Biochemistry from the National Institute of Immunology, India.
In the Greenberg lab, Dr. Verma’s research focused on understanding how BRCA-mutated ovarian cancer cells rewire their DNA repair mechanisms to survive the functional loss of BRCA proteins. Understanding these compensatory pathways will help identify new genes that are synthetically lethal with BRCA-deficiency and will also reveal new mechanisms that confer resistance to poly (ADP-ribose) polymerase inhibitors (PAPRi)-based targeted therapies. To understand these BRCA-independent DNA repair mechanisms, her research employed a unique model of alternative lengthening of telomeres (Dilley R, Verma P et al. Nature 2016; Verma P et. al. Genes Dev 2019; Verma P et al. Methods in Enzymology 2018), where DNA synthesis in response to DNA double-strand breaks occurs in a BRCA-independent manner, as well as various biochemical assays and powerful CRISPR/Cas9 genetic screening technology. This genetic screen was performed in collaboration with Dr. Junwei Shi at UPenn, who pioneered the use of this technology to identify new drug targets in various cancer subtypes. Dr. Verma recently published a first-author article (Verma P, et. al. Nat Cell Biol, 2021) that identified ALC1 as a promising new drug target for BRCA mutant cancers.
Dr. Verma is now an Assistant Professor in the Department of Medicine at Washington University in St. Louis Medical School.
Dr. Tian received her Bachelor of Medicine (MBBS) and master's degree in Hematology from Tongji Medical College in China. She went on to obtain her PhD in Toxicology from University of Kentucky, focusing on DNA mismatch repair mechanism. In the Greenberg lab, Dr. Tian's work focused on the deubiquitinating enzyme’s function in DNA repair and inflammation signaling. She has published first-author papers in Cancer Discovery that identified mutations in BRCA1 as a cause of Fanconi Anemia and in Nature that described a new mechanism of communication between metabolic control of deubiquitinating enzyme activity and immune responses. Dr. Tian is now a senior scientist at Esai Pharmaceuticals.
Mischa completed her MD/PhD in the Greenberg lab, defending her thesis "TIP60-dependent histone acetylation promotes DNA repair by homologous recombination" on November 13, 2018. She came to Penn after completing her undergraduate research at Stanford University School of Medicine. During her time in the Greenberg lab, she was the first author on an article that showed phosphorylation directs TIP60-dependent acetylation to promote homologous recombination and maintain genome stability (Li M, et. al., Mol Cell Biol, 2018). Mischa is currently a Clinical Pathology resident doctor at Brigham and Women's Hospital in Boston, MA.
As the recipient of the Tarble Summer Research Fellowship (Swarthmore College, Biology dept.) over the summer of 2018, Monie conducted cancer genetics research under Prof. Dawn Carone. During the following year, she continued researching a non-coding high-copy tandem RNA sequence of interest using cancerous PC3 cells. She recently graduated from Swarthmore College with a B.A., in Biology and Psychology. Currently, Monie is a Research Specialist working with Dr. Priyanka Verma in the Greenberg Lab. Monie authored a paper with Dr. Verma (Verma P, et. al., Nat Cell Biol, 2021) that identified ALC1 as a promising new drug target for BRCA mutant cancers. During her time in the lab, Monie examined the underlying mechanisms of genomic stability various CRISPR based genetic screens. She is currently working as a research assistant in a psychology lab at CHOP.
Dr. Yang received her B.S. in the School of Life Sciences, Jilin Normal University, Siping, China, followed by her M.S. in the Key Laboratory of Molecular Epigenetics of MOE, Unit of Plant Epigenetics, Institute of Genetics & Cytology, Northeast Normal University, Changchun, China. She then went on to obtain her PhD in the Laboratory of Transcription, Chromatin and DNA Repair, Section for Functional Genomics, Department of Biology, Faculty of Science, University of Copenhagen, Copenhagen, Denmark. There she studied regulatory mechanisms of DNA repair factors in response to DNA damage in the budding yeast Saccharomyces cerevisiae. Dr. Yang's research in the Greenberg lab was to dissect the regulatory function of deubiquitinating enzyme BRCC36 within BRCA1-RAP80 complex in recognizing and responding to DNA damage, and explore the regulatory mechanism of Shieldin complex in determining DNA repair pathway choice. Dr. Yang is currently exploring biotech options in China.
Robert Dilley obtained his Bachelor’s of Science from The Johns Hopkins University in 2011. He began his Graduate studies at UPenn in 2012 and joined the Greenberg lab in 2014. He authored several papers while in the lab, one of which as a first author showed that inception of telomere damage recognition by the break-induced replisome orchestrates homology-directed telomere maintenance (Dilley R, et. al. Nature, 2016). He received the Saul Winegrad Award for Outstanding Dissertation in 2019 for his thesis "Mechanisms of Telomere Repair Synthesis." After completing his medical school studies in May of 2021, Robert will continue his training at the Massachussetts General Hospital for Internal Medicine in the physician-scientist program.
Qinqin Jiang obtained her Bachelor’s of Science from University of Hong Kong, Hong Kong in 2011. She defended her thesis "Molecular Recognition at DNA Damage Sites" on April 6, 2018. Qinqin has a first author paper on the BRCA1-A complex in Genes & Development (Jiang Q et al., Genes Dev, 2015) and a first author review article (Jiang Q and Greenberg RA, J Biol Chem., 2015). Qinqin is currently a Research Fellow in Nobel Laureate, Dr. Bill Kaelin’s lab at the Dana Farber Research Institute.
Namwoo (Will) Cho completed his undergraduate studies at Harvard Medical School, and joined the Greenberg lab in 2013. Will authored multiple publications during his time in the lab, most notably as first author on a paper showing a molecular basis underlying the preference for recombination between nonsister telomeres during ALT (Cho NW, et. al., Cell, 2014; and see bibliography). He received the Saul Winegrad Award for Outstanding Dissertation, 2016, for his thesis defense (Homologous Recombination-Directed Mechanisms of Alternative Lengthening of Telomeres). Since leaving the lab, Will completed a Preliminary Medicine Internship at St. Mary’s Medical Center, San Francisco, CA, and is currently a Radiation Oncology Resident in the Holman Research Residency program in Radiation Oncology at UCSF and is a fellow in Matthew Spitzer’s lab.
Shane Harding earned his PhD in Medical Biophysics in the lab of Robert Bristow at the University of Toronto. He completed his Postdoctoral work on mechanisms of communication between DNA damage and immune responses in the Greenberg Lab in 2018. Dr. Harding authored multiple papers during his time in the lab, including a landmark study in Nature on DNA damage and immune activation (see bibliography). Shane is currently an Assistant Professor at the Princess Margaret Cancer Centre, University Health Network, and the Dept. of Medical Biophysics at the University of Toronto in Toronto, Canada.
Yaroslav Morozov PhD earned his PhD at Rowan University and did his postdoctoral research in the Greenberg lab from 2019-2021 while investigating the structural determinants of the BRCA1-A complex. He is now a Principal Scientist at Sanofi Pharmaceuticals.
Niraj Shanbhag earned his Bachelors of Science from Cornell University in 2005. Niraj was first author of an article in Cell that delved into an ATM-dependent transcriptional silencing program in cis to DSBs (Shanbhag N, et. al., Cell 2010). Upon completing his thesis research in the Greenberg Lab in 2012, Niraj received the Saul Winegrad Award for Outstanding Dissertation, titled "Communictaion between DNA damage and transcription." Niraj went on to complete a Postdoctoral Fellowship at Gladstone Institutes in San Francisco, CA. He is currently the Medical Director at Vertex Pharmaceuticals in Boston, MA.
During his time as a graduate student in the Greenberg lab, Jeffrey Patterson-Fortin studied Ubiquitin targeting and editing in cellular responses while on a Canadian Institute of Health Research Fellowship. Jeffrey was first author on multiple papers on the BRCA-A complex, and made major advances towards understanding how JAMM domain DUB activity is regulated at the biochemical and cellular levels (Patterson-Fortin J, et. al., J Biol Chem, 2010; Shao G, Patterson-Fortin J, et. al., Genes Dev, 2009; Solyom, Patterson-Fortin J., et al. Sci Transl Med, 2012; Zheng et al. Cell Rep, 2013). Upon completing his thesis in 2015, he went on to complete a Residency of Internal Medicine/Genetics at Johns Hopkins Hospital, and Residency of Oncology and postdoctoral fellowship (Alan D’Andrea post-doc mentor) at the Dana-Farber Cancer Institute, where he is currently a Clinical Fellow in Oncology.
After obtaining her Bachelor’s degree in neuroscience from the College of William & Mary, Kara completed her doctorate in the Greenberg Lab on DNA end resection in 2011. During that time, she authored first-author papers with Dr. Greenberg (Coleman K, and Greenberg RA, J Biol Chem, 2011; and Nikkilä J, et. al., Oncogene, 2009). She went on to develop medical education content for ETHOS Health Communications, and was promoted to Scientific Director. Kara is now Project Director of Biomedical Programs at The Pew Charitable Trusts.
Genze Shao completed his PhD studies at Peking Union Medical School and performed postdoctoral studies in the Greenberg lab from 2007-2010, where he worked on DNA damage response functions of the BRCA1-A complex. During that time, he produced first-authored papers revealing a Rap80-BRCC36 dependent pathway important to DNA repair (Shao G, et. al., Proc Natl Acad Sci USA, 2009) and the discovery of the MERIT40 protein (Shao G, et al., Genes Dev., 2009). He became an Assistant Professor at the Peking Union Medical School in 2010 and was promoted to Associate Professor in 2014.
Jiangbo Tang completed his PhD studies at the University of Pittsburgh with Dr. Robert Sobol. He performed postdoc studies of chromatin mechanisms of DNA repair in the Greenberg lab from 2010-2013. Jiangbo was first author of a paper during this time that outlined a role for 53BP1 in promoting homologous recombination (Tang J, et. al., Nat Struct Mol Biol., 2013). He joined Alliance Pharma and worked there for three years before moving to Next Advance as an operations manager. He then started his own company, CisNovo that sells consumables and instruments to research laboratories. Dr. Tang is currently a staff scientist at Regeneron.
Troy Messick completed his Postdoctoral Fellowship in the Greenberg Lab in 2009 on the BRCA1-A complex. During this time, he authored a paper on MERIT40 with fellow lab members (Shao G, et. al, Genes Dev, 2009), and was first author of a review with Dr. Greenberg discussing how ubiquitin structures may influence DNA damage responses (Messick T, and Greenberg RA, J Cell Biol., 2009). Troy spent two years after this as Vice President of Vironika LLC, a drug discovery company, before becoming an Investigator at The Wistar Institute in 2011. He is currently a Staff Scientist and Program Director at The Wistar Institute.
Vibhor Gupta performed his PhD studies in India while studying metabolism. Dr. Gupta performed his postdoctoral reserach in the Greenberg lab from 2012-2015 while studying metabolic control of ubiquitin dependent innate immune responses. Notably he was a first author on a paper suggesting a therapeutic use for BRISC inhibitors in treating pathophysiological processes driven by elevated IFN responses (Zhang Hui, Gupta V, et. al., Cell Rep., 2013). He is now the Associate Director of Cell & Gene Therapy at Absorption Systems.
Laura Butler performed her PhD studies with Dr. Jo Morris at the University of Birmingham. She performed postdoctoral research in the Greenberg lab from 2014-2016 working on chromatin mechanisms of DNA repair. She then worked as a scientist at ATRIN Pharmaceuticals and is now a Team Leader at PhoreMost LTD, a new-model drug discovery company based in Cambridge, UK.
Bernadette Aressy performed her PhD studies on cell cycle control of DNA repair in Toulouise, France. She was a postdoc in the Greenberg lab from 2010 to 2013. Bernadette published several papers while in the lab, notably on the role of MERIT40 on ICL repair (Jiang Q, et. al., Genes Dev., 2015) and a first-author commentary on DNA damage (Aressy B, and Greenberg RA, Curr Biol., 2012) She is now a consultant with ZS Associates.
Dr. Hum received her Bachelor of Science from University of Wisconsin-Madison and her Ph.D. in Genetics and Genomics from Duke University. For her graduate work, she studied the molecular mechanism of homologous recombination in baker’s yeast with Dr. Sue Jinks-Robertson. In the Greenberg lab, Dr. Hum addressed fundamental questions regarding the mechanisms underlying micronuclei formation and human cancer genome evolution. She is now working at a biotech company in Singapore.